🇯🇵·13h agoIndustry
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy
Publisher
O
Otsuka Holdings RSS
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Otsuka Holdings RSS
- Region
- Japan
- Scope
- Industry
- Published
- August 4, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on otsuka.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Holdings RSS
Scope: Industry
Related coverage
More related coverage
SELLAS Life Sciences/6h ago
Clinical Trials - Sellas Life Sciences
Sumitomo Pharma/7h ago
Sumitomo Pharma Contributes to Relief Efforts for the 2026 Kumamoto Earthquake
Sumitomo Pharma/8h ago
Regarding a Report Concerning Sumitomo Pharma
Monash Health/10h ago